ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

Volume 556
June 7, 1989

HEPARIN AND RELATED POLYSACCHARIDES[a]

STRUCTURE AND ACTIVITIES

Editors

FREDERICK A. OFOSU, ISIDORE DANISHEFSKY, AND JACK HIRSH

CONTENTS

Preface. *By* FREDERICK A. OFOSU, ISIDORE DANISHEFSKY, AND JACK HIRSH xi

Part I. Structure of Heparin & Related Polysaccharides

Structure of Heparin and Heparin Fragments. *By* BENITO CASU 1

Structure of Heparan Sulfate and Dermatan Sulfate. *By* H. EDWARD CONRAD 18

Location of Specific Units in Heparin and Heparan Sulfate. *By* ISIDORE DANISHEFSKY, LOUIS ROSENFELD, LORRAINE KUHN, BISWAJIT LAHIRI, AND CAROL WHYZMUZIS 29

Biosynthesis of Heparin and Heparan Sulfate. *By* ULF LINDAHL, MARION KUSCHE, KERSTIN LIDHOLT, AND LARS-GÖRAN OSCARSSON 36

Cell-Surface Proteoheparan Sulfate Structure-Function Relationships. *By* JEREMIAH E. SILBERT, PEGGY JO GILL, DONALD E. HUMPHRIES, AND CYNTHIA K. SILBERT 51

Chemically Synthesized Heparin-Derived Oligosaccharides. *By* JEAN CHOAY 61

Part II. Anticoagulant Mechanisms: Interactions of Glycosaminoglycans with Heparin Cofactors

Kinetics of Heparin Action. *By* JOSEPH D. SHORE, STEVEN T. OLSON, PAUL A. CRAIG, JEAN CHOAY, AND INGEMAR BJÖRK 75

Role of Endothelial Cell Surface Heparin-like Polysaccharides. *By* JAMES A. MARCUM AND ROBERT D. ROSENBERG 81

[a] This volume is the result of a conference entitled Structure and Activities of Heparin and Related Polysaccharides, which was held in New York City on November 3–5, 1987 by the New York Academy of Sciences.

Effect of Heparin on the Inhibition of the Contact System Enzymes. *By* Robert W. Colman, Cheryl F. Scott, Robin A. Pixley, and Raul A. De La Cadena 95

Physicochemical Aspects of Heparin Cofactor II. *By* Charlotte W. Pratt, Herbert C. Whinna, James B. Meade, Rita E. Treanor, and Frank C. Church 104

Heparin Cofactor II Activation by Dermatan Sulfate. *By* Douglas M. Tollefsen, Margaret M. Maimone, Elizabeth A. McGuire, and Monita E. Peacock 116

Plasma Anticoagulant Mechanisms of Heparin, Heparan Sulfate, and Dermatan Sulfate. *By* Frederick A. Ofosu, M. R. Buchanan, N. Anvari, L. M. Smith, and M. A. Blajchman 123

Anticoagulant Activities of Heparin and Fragments. *By* T. W. Barrowcliffe and D. P. Thomas 132

The *ex Vivo* Correlate of the Antithrombotic Action of Heparin. *By* H. C. Hemker, S. Béguin, J. Pieters, and T. Lindhout 146

Part III. Interactions of Glycosaminoglycans with Other Macromolecules

Thrombin Anion-binding Exosite Interactions with Heparin and Various Polyanions. *By* John W. Fenton II, Joyce I. Witting, Craig Pouliott, and Jawed Fareed 158

A New Method for Purifying Heparin-binding Growth Factors. *By* Y. Shing, M. Klagsbrun, and J. Folkman 166

Interaction of Lipoprotein Lipase with Heparin. *By* Kazuhiro Oka, Patsy Wang-Iverson, James R. Paterniti, Jr., and W. Virgil Brown 173

Interaction of Heparin with Histidine-rich Glycoprotein. *By* H. R. Lijnen and D. Collen 181

Interaction of Glycosaminoglycans with Lipoproteins. *By* Alan D. Cardin, Richard L. Jackson, Doris A. Sparrow, and James T. Sparrow 186

Heparan Sulfate Proteoglycans of *Ras*-Transformed 3T3 or Neuroblastoma Cells: Differing Functions in Adhesion on Fibronectin. *By* Lloyd A. Culp, Gabriele Mugnai, Kristine Lewandowska, Elizabeth A. Vallen, Mary A. Kosir, and Kathryn L. Houmiel 194

Part IV. Interactions of Glycosaminoglycans with Cells

In Vitro Studies of the Interaction of Heparin, Low Molecular Weight Heparin and Heparinoids with Platelets. *By* Harry L. Messmore, Jr., Beth Griffin, Jawed Fareed, Erwin Coyne, and Jerhard Seghatchian 217

Influence of the Fibroblast Environment on the Structure of Mast Cell Proteoglycans. *By* MARC E. ROTHENBERG AND K. FRANK AUSTEN .. 233

Effects of Unfractionated Heparin, Dermatan Sulfate and Low Molecular Weight Heparin on Vessel Wall Permeability in Rabbits. *By* M. A. BLAJCHMAN, E. YOUNG, AND F. A. OFOSU 245

Heparin and Growth Control of Vascular Cells. *By* ROBERT W. THOMPSON, ALICIA ORLIDGE, AND PATRICIA A. D'AMORE..... 255

Heparin, Heparan Sulfate, Smooth Muscle Cells, and Atherosclerosis. *By* M. J. KARNOVSKY, T. C. WRIGHT, JR., J. J. CASTELLOT, JR., J. CHOAY, J.-C. LORMEAU, AND M. PETITOU 268

Part V. Animal Studies

Pharmacokinetics of Heparin and Related Polysaccharides. *By* B. BONEU, F. DOL, C. CARANOBE, P. SIE, AND G. HOUIN 282

Pharmacokinetic and Biological Activities of Dermatan Sulfate (Mediolanum MF701) in Healthy Human Volunteers. *By* J. DAWES, B. A. HODSON, I. R. MACGREGOR, D. S. PEPPER, AND C. V. PROWSE 292

Effects of Dermatan Sulfate and Heparin on Inhibition of Thrombus Growth *in Vivo*. *By* JOANNE VAN RYN-MCKENNA, FREDERICK A. OFOSU, ELAINE GRAY, JACK HIRSH, AND MICHAEL R. BUCHANAN .. 304

Relative Efficacy of Heparin and Related Glycosaminoglycans as Antithrombotic Drugs. *By* D. P. THOMAS, R. E. MERTON, AND T. W. BARROWCLIFFE 313

Antithrombotic Effects of Heparin Oligosaccharides. *By* CH. MATTSSON, M. PALM, K. SÖDERBERG, AND E. HOLMER..... 323

Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins. *By* J. FAREED, J. M. WALENGA, D. HOPPENSTEADT, X. HUAN, AND R. NONN..... 333

Influence of Platelet Factor 4 on the Neutralization of Heparin by Protamine. *By* J. N. SHANBERGE & T. M. QUATTROCIOCCHI-LONGE . 354

The Issue of Animal Models of Thrombosis. *By* STANFORD WESSLER..... 366

Part VI. Clinical Studies

Heparin for Prophylaxis of Venous Thromboembolism. *By* EDWIN W. SALZMAN..... 371

Heparin Therapy in Venous Thromboembolism. *By* J. HIRSH 378

Clinical Studies with Low Molecular Weight Heparins in the Prevention and Treatment of Venous Thromboembolism. *By* M. SAMAMA, J. P. BOISSEL, S. COMBE-TAMZALI, AND A. LEIZOROVICZ 386

Heparin in the Treatment of Thromboembolic Stroke. *By* A. G. G. Turpie, R. Bloch, and R. Duke 406

Part VII. Poster Papers

Further Purification of Heparin Reduces Its Bleeding Effects in the Mesenteric Vessels of Rats. *By* Guiliana Andriuoli, Gaetano D'Atri, Giorgio Galimberti, Monique Sarret, Giorgio Zoppetti, Benito Casu, Annamaria Naggi, Pasqua Oreste, and Giangiacomo Torri 416

Antiviral Activity of Heparin and Dextran Sulfate against Human Immunodeficiency Virus (HIV) *in Vitro*. *By* Masanori Baba, Rudi Pauwels, Jan Balzarini, Jan Desmyter, and Erik de Clercq .. 419

Heparin Solubilizes Many Tissue Components. *By* Bonnie Anderson Bray and Gerard M. Turino 422

The Effect of Heparin, Heparin Fractions, and Factor IIa Inhibitors on Laser-induced Thrombus Formation in Rat Mesenteric Vessels. *By* H. K. Breddin, W. Weichert, and K. Krupinski 425

Kinetics of Human Platelet Factor 4 in Rabbits: Effect of Glycosaminoglycans and Protamine Sulfate. *By* G. Cella, M. Prosdocimi, A. Zatta, G. Luzzatto, P. Simioni, F. Stevanato, and A. A. Sasahara 429

Role of Heparin and Heparin Fraction in Leukocyte Count: An Experimental Study. *By* C. Doutremepuich, C. Anne, F. Pereira, O. de Seze, F. Doutremepuich, C. Vigneron, F. Toulemonde, and A. de Mascarel 432

tPA-Like Activity of an Experimental Thrombus in the Presence of Heparin and a Heparin Fraction. *By* C. Doutremepuich, O. de Seze, F. Doutremepuich, C. Anne, T. Castrioto, and F. Toulemonde 435

Inhibition of Heparanase Activity by Heparin and Nonanticoagulant Heparins: Potential Use in Prevention of Extravasation and Dissemination of Blood-Borne Cells. *By* Amiram Eldor, Matia Bar-Ner, Lina Wasserman, Yaacov Matzner, Zvi Fuks, and Israel Vlodavsky 437

Plasma Fibrin Degradation Products Evolution in Patients with Deep-Vein Thrombosis Treated with a Low Molecular Weight Heparin Fraction (CY222) and Standard Heparin. *By* Rene Faivre, Eric Neuhart, Claudine Soria, Jeannette Soria, Yvonne Kieffer, Dominique Ducellier, Jean Pierre Bassand, Jacques Caen, and Jean Pierre Maurat 441

Comparison of Antiplatelet Aggregatory and Antithrombotic Activity of Low Molecular Weight RD Heparin with Heparin. *By* R. L. Fenichel, W. Carmint, B. Small, and J. Willis 444

Heparin Requirements in Coronary Angioplasty. *By* J. G. Franke, R. R. Mildenberger, G. W. MacKenzie, J. E. Morch, M. B. Williams, R. T. Brownlee, and G. D. Kemna 447

Specific Actions of Heparin and the Reasons for Usage and Nonusage by Clinicians. *By* Orville Horwitz, John J. Sayen, Brooke Roberts, and W. T. M. Johnson 450

Heparin Neutralizing Proteins in Blood. *By* D. A. Lane 453

Heparin and Low Molecular Weight Heparin(oid)s as Anticoagulants in Hemodialysis for Chronic Renal Failure. *By* D. A. Lane, C. Tew, H. Ireland, A. Flynn, and J. Curtis 456

Inhibition of the Anticoagulant Properties of Antithrombin III and Heparin by Fibrin. *By* Corinne M. Linardic and Charles S. Greenberg 459

Heparin and Concanavalin A Interaction: A Useful Model for Studying the Mechanism of Anticoagulant Activity. *By* Juan Carlos Monge, Cecilia Legorburu, Marta Fernández de Recondo, and Eduardo F. Recondo 462

Dermatan Sulfate Induces tPA Release in the Perfused Rat Hindquarters. *By* L. Mussoni, M. Abbadini, G. J. Zhu, A. Maggi, J. Pangrazzi, and M. B. Donati 465

Bleeding Effects Associated with Heparin Contaminants. *By* J. Pangrazzi, P. Oreste, A. M. Naggi, G. Torri, A. Maggi, M. B. Donati, and B. Casu 468

NMR Spectra of Heparin in Admixture with Dermatan Sulfate and Other Glycosaminoglycans. *By* Arthur S. Perlin and Kevin R. Holme . 471

Antagonism of the Antithrombotic Effects of Heparin and Fraxiparine® in a Rat Model of Laser-induced Thrombosis. *By* A. Racanelli, H. K. Breddin, K. Krupinski, and J. Fareed 473

Long-Term Flexible Dose Heparin in Coronary Heart Disease: Correlation of Frequency of Cardiovascular Events with Different Heparin Dosage Levels, and Observations on Comparative Mortality. *By* John J. Sayen, Richard B. Singer, George Peirce, Leslie T. Cooper, and Orville Horwitz 476

Characterization of Epidermal Keratins during Fetal Pig Skin Development. *By* C. A. Signor and T. Kurihara-Bergstrom 480

Randomized Double-blind, Placebo-controlled Study of the Effects of a Low Molecular Weight Heparinoid on Urinary Blood Loss following Transurethral Resection of the Prostate. *By* Hugo ten Cate, Ch. Pieter Henny, Jan W. ten Cate, Harry R. Büller, and Nosjer F. Dabhoiwala 483

In Vitro Study of a New Potential Antithrombotic Drug MF 701 (Dermatan Sulfate). *By* P. Toulon, M. Aiach, and F. Gianese 486

Structure-Activity Relationships of Synthetic Heparin Fragments: Discovery of a Very Potent ATIII Activating Pentasaccharide. *By* C. A. A. VAN BOECKEL, S. F. VAN AELST, T. BEETZ, D. G. MEULEMAN, TH. G. VAN DINTHER, AND H. C. T. MOELKER 489

Kinetic Investigation of the Inhibition of Lysozyme by Heparin. *By* I. M. A. VERHAMME, A. R. LAUWERS, AND G. W. K. VAN DEDEM . 492

Heparin Derivatives as Inhibitors of Heparanase from Metastatic Melanoma Cells. *By* GERMAN B. VILLANUEVA, MOTOWO NAKAJIMA, AND GARTH L. NICOLSON 496

Index of Contributors 499

Major funding for this conference was provided by:

- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE / NIH

Financial assistance was received from:

- BRISTOL-MYERS COMPANY
- DIOSYNTH B. V.
- HOECHST-ROUSSEL PHARMACEUTICALS INC.
- INSTITUT CHOAY
- MEDIOLANUM FARMACEUTICI S.r.l.
- MERCK SHARP & DOHME RESEARCH LABORATORIES
- MERRELL DOW RESEARCH INSTITUTE
- MILES LABORATORIES
- ORGANON INTERNATIONAL B. V.
- THE UPJOHN COMPANY
- WYETH LABORATORIES

The New York Academy of Sciences believes it has a responsibility to provide an open forum for discussion of scientific questions. The positions taken by the participants in the reported conferences are their own and not necessarily those of the Academy. The Academy has no intent to influence legislation by providing such forums.